Clinical trials: CYP2C19 Poor
CYP2C19 Poor, Extensive Metabolizers
Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin
The main purpose of this study is to examine Taiwanese subjects identified as CYP2C19 poor and extensive metabolizers while taking single and multiple dosing a rosuvastatin calcium.
- Trial name
- NCT00766025
- Testing
- Rosuvastatin Calcium
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease, Huntington's Disease
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
- Trial name
- NCT00931073
- Testing
- Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Peptic Ulcer With H. Pylori Infection, Gastritis With H. Pylori Infection
The Role of CYP2C19 on the Eradication of H. Pylori Infection:Implication of PK/PD Relationships
The objective of this trial is to find the rationale and the optimal dose and duration of regimen for the eradication of H. pylori infection using different proton pump inhibitors.
- Trial name
- NCT00162877
- Testing
- Rabeprazole vs. Esomeprazole
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management (MTM) program has a beneficial impact on drug therapy problems.
- Conditions
- Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Trial name
- NCT02428660
- Testing
- Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- Genelex Corporation
Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant
Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole
The family of cytochrome P450 (CYP) is the most important drug metabolizing enzymes which contributes to the metabolism of a large proportion of drugs in humans.
- Trial name
- NCT03092193
- Testing
- Naproxen, Naproxen-esomeprazole
- Where
- Brazil
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Healthy
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
The objective of the current study is to evaluate the effect of once daily itraconazole on the pharmacokinetics of BI 409306 in poor (PM) and extensive metabolisers (EM) of CYP2C19.
- Trial name
- NCT02248259
- Testing
- BI 409306, Itraconazole
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Adverse Drug Events, Adverse Drug Reactions
YouScript IMPACT Registry
This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized…
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- IMPACT (NCT02191358)
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Genelex Corporation
Advanced/Recurrent Non-small-cell Lung Cancer
A Study of ARQ 197 in Combination With Erlotinib
This is a phase I study to determine the safety, tolerability and recommended phase II dose of ARQ 197 given in combination with erlotinib as primary endpoints in CYP2C19 poor metabolizer patients with advanced/recurrent…
- Trial name
- NCT01251796
- Testing
- ARQ 197 and Erlotinib
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Kyowa Kirin Co., Ltd.
CLOPIDOGREL, POOR METABOLISM of (Disorder)
Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Clopidogrel, in addition to aspirin, is the cornerstone of therapy in patients suffering from Acute coronary syndrome. However, the platelet inhibitory response to clopidogrel varies substantially among individuals.
- Trial name
- GI-CT (NCT02048228)
- Testing
- genotyping guided therapy Ticagrelor, Clopidogrel, standard therapy clopidogrel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Healthy Volunteers
Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM
A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers
- Trial name
- NCT02906176
- Testing
- Vfend (voriconazole) intravenous infusion, Vfend (voriconazole) tablet
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype
To assess the PK and safety profiles of ARQ 197 in extensive and poor metabolizers, as defined by CYP 2C19 genotype
- Trial name
- NCT00651638
- Testing
- Treatment with ARQ 197
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Pharmacogenomic Drug Interaction, Side Effect of Drug
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed…
- Conditions
- Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related
- Trial name
- PREPARE-Mayo (NCT06322238)
- Testing
- PGx panel test
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic